Navigieren durch die EU-MDR: Was sie für Ihre Materialauswahl bedeutet

The introduction of the EU MDR (2017/745) marks one of the most significant regulatory shifts the medical device industry has experienced in decades. While earlier directives focused primarily on product approval, the new framework takes a broader, more demanding view—placing equal weight on safety, transparency, traceability, and long-term performance.

For manufacturers working with inflatable medical devices, including air mattresses, pressure therapy sleeves, rehabilitation cuffs, and fluid control bladders, the impact is especially direct. These products rely heavily on flexible materials, coatings, and bonded structures, all of which now fall under deeper regulatory scrutiny.

Material selection, once driven largely by cost-performance balance, is now closely tied to regulatory compliance. Every layer—whether it is a base fabric, coating, adhesive, or additive—must be justified, documented, and traceable.

In practical terms, this means manufacturers can no longer rely on generic material specifications or incomplete supplier documentation. Instead, they must build a material strategy that aligns with biocompatibility standards, chemical safety expectations, and supply chain transparency requirements.

Among the material options available, medical-grade TPU fabric has emerged as a strong candidate for MDR-aligned design, not only because of its performance characteristics but also due to its compatibility with regulatory expectations.

The Shift from Product Approval to Lifecycle Accountability

One of the most important changes under EU MDR is the move from a static approval model to a continuous lifecycle approach. Approval is no longer the end goal—it is just one step within an ongoing process of monitoring, validation, and improvement.

Under this framework, manufacturers must demonstrate control over every stage of the product lifecycle:

• Material selection and design rationale
• Manufacturing consistency and process validation
• Real-world performance through post-market surveillance
• End-of-life considerations and risk management

This shift fundamentally changes how materials are evaluated. Instead of simply meeting initial specifications, materials must perform reliably over time and under varying real-world conditions.

For example, in inflatable medical products, materials are often subjected to repeated stress cycles, pressure changes, temperature variation, and prolonged skin contact. Under MDR, these conditions must be considered upfront, and the selected materials must be able to maintain stability and safety throughout their expected lifespan.

Additionally, post-market surveillance (PMS) now plays a critical role. Manufacturers must actively collect and analyze data related to product performance, including any material-related failures. If a material contributes to device malfunction or adverse events, it must be traceable back to its source.

This is where material choice directly influences regulatory risk. A well-documented, stable material reduces uncertainty, while poorly defined materials introduce gaps that can become compliance issues later.

Material Transparency Is No Longer Optional

EU MDR introduces a much higher expectation for material transparency. Manufacturers are required to have detailed knowledge of every substance used within their device, including those that may not have been fully disclosed under previous frameworks.

This includes:

• Base polymers and substrates
• Coatings and surface treatments
• Additives such as plasticizers, stabilizers, and pigments
• Residual chemicals from processing

The regulation places particular emphasis on identifying and assessing potentially hazardous substances, including those that may migrate during use.

For inflatable structures made from coated textiles, this creates a more complex validation process. A TPU-coated fabric, for example, is not evaluated as a single material—it is assessed as a system consisting of multiple components.

Each of these components must be evaluated for:

• Chemical stability
• Interaction with the human body
• Potential for extractables and leachables
• Long-term degradation behavior

Compared to traditional materials such as PVC, which often rely on plasticizers that can migrate over time, TPU offers a more stable chemical profile. This stability simplifies the process of demonstrating compliance with MDR requirements.

Biocompatibility: From Certification to Evidence-Based Evaluation

Biocompatibility has always been part of medical device regulation, but under EU MDR, the expectations have shifted significantly.

Instead of relying on generic certifications, manufacturers must now conduct device-specific, risk-based biocompatibility assessments in accordance with ISO 10993.

This involves:

• Identifying all materials that come into contact with the body
• Determining the type and duration of contact
• Conducting appropriate biological evaluations
• Supporting findings with chemical characterization data

For inflatable medical devices, common concerns include:

• Skin irritation from prolonged contact
• Sensitization caused by additives
• Toxicity from leachable substances

To address these risks, manufacturers must go beyond surface-level testing. They need to understand how materials behave under actual use conditions, including exposure to heat, moisture, pressure, and body fluids.

This is where medical-grade TPU demonstrates clear advantages. Its formulation is typically controlled to minimize impurities and reduce the presence of migratory substances, making it easier to achieve consistent biocompatibility results.

Documentation Depth and Technical File Expectations

Under EU MDR, documentation is no longer just a supporting element—it is central to compliance.

Every material used in a device must be fully documented within the technical file, including:

• Detailed material composition
• Mechanical and physical performance data
• Biocompatibility test results
• Chemical characterization reports
• Supplier certifications and declarations

For inflatable medical products, this often means obtaining batch-level traceability from material suppliers. Manufacturers need to know not only what materials are used, but also where they come from, how they are produced, and how consistent they are across different production runs.

Incomplete documentation is one of the most common reasons for delays during regulatory review. Even if a material performs well in practice, lack of supporting data can create significant obstacles.

Working with suppliers that provide comprehensive technical data packages helps reduce this risk and ensures that all required information is readily available during audits.

Supplier Qualification and Long-Term Control

The role of suppliers has expanded significantly under EU MDR. Material suppliers are no longer just vendors—they are part of the overall compliance framework.

Manufacturers are expected to evaluate and monitor their suppliers to ensure:

• Consistent product quality
• Controlled manufacturing processes
• Reliable documentation and traceability
• Clear communication regarding changes

In most cases, this requires suppliers to operate under a certified quality management system, such as ISO 13485.

For manufacturers of inflatable medical devices, this is particularly important. Variations in material thickness, coating uniformity, or bonding performance can directly affect device safety and functionality.

Choosing a supplier with a mature quality system reduces variability and provides greater confidence in long-term product performance.

Managing Material Changes Under MDR

One of the more challenging aspects of EU MDR is the strict approach to change management.

Any change to materials—including formulation adjustments, supplier changes, or process modifications—must be evaluated for its potential impact on safety and performance.

If the change is considered significant, it may require:

• Additional testing
• Updates to technical documentation
• Notification to regulatory authorities

For manufacturers, this means stability becomes a key factor in material selection. Frequent or poorly controlled changes can create ongoing compliance challenges.

Reliable materials, supported by stable supply chains, help minimize the need for revalidation and reduce regulatory complexity over time.

Why TPU Materials Align Well with MDR Requirements

In the context of these regulatory changes, medical-grade TPU fabric stands out as a material that aligns naturally with MDR expectations.

From a performance perspective, TPU offers:

• High flexibility and durability
• Strong resistance to hydrolysis and environmental stress
• Excellent sealing properties for inflatable structures

From a compliance perspective, it provides:

• A cleaner chemical profile with fewer additives
• Greater stability over time
• Easier characterization in extractables and leachables studies
• Strong documentation support from established suppliers

These characteristics make TPU not only a technically capable material, but also a practical choice for navigating regulatory requirements.

Building a Material Strategy for MDR Compliance

To adapt to EU MDR, manufacturers need to take a more structured approach to material selection.

This typically involves:

• Reviewing existing materials and identifying compliance gaps
• Upgrading supplier requirements to include detailed technical documentation
• Integrating material data into internal quality systems
• Establishing closer collaboration with key suppliers

Rather than treating materials as interchangeable components, companies are increasingly viewing them as strategic assets that influence both compliance and product performance.

Looking Ahead: Materials as a Competitive Advantage

As the industry continues to adapt to EU MDR, material selection is becoming a key differentiator.

Manufacturers that invest in compliant, well-documented materials are better positioned to:

• Accelerate certification timelines
• Reduce regulatory risk
• Improve product reliability
• Strengthen market competitiveness

In contrast, those relying on outdated or poorly documented materials may face delays, increased costs, and greater uncertainty.

EU MDR has fundamentally changed the way medical devices are developed, evaluated, and maintained. For manufacturers of inflatable medical products, these changes are closely tied to material selection.

Choosing a material such as medical-grade TPU fabric is no longer just about performance—it is about building a foundation for compliance, reliability, and long-term success.

In this environment, the relationship between manufacturers and material suppliers becomes more important than ever. Companies that prioritize transparency, documentation, and consistency will find it easier to navigate the regulatory landscape and bring safer, more reliable products to market.